NEOS Investment Management LLC Acquires 1,754 Shares of Charles River Laboratories International, Inc. $CRL

NEOS Investment Management LLC boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 26.2% in the second quarter, Holdings Channel.com reports. The fund owned 8,444 shares of the medical research company’s stock after buying an additional 1,754 shares during the quarter. NEOS Investment Management LLC’s holdings in Charles River Laboratories International were worth $1,915,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Continuum Advisory LLC acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $30,000. Los Angeles Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $42,000. Sfam LLC bought a new stake in Charles River Laboratories International in the fourth quarter valued at about $43,000. Geneos Wealth Management Inc. increased its holdings in Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new position in Charles River Laboratories International in the fourth quarter valued at about $46,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CRL shares. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Robert W. Baird set a $291.00 price objective on shares of Charles River Laboratories International in a research note on Thursday, August 6th. Barclays reaffirmed an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Finally, Morgan Stanley increased their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Insider Activity

In other news, CAO Michael Knell sold 6,645 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the transaction, the chief accounting officer directly owned 11,852 shares of the company’s stock, valued at $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 165,990 shares of company stock worth $42,606,388. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $289.40 on Tuesday. The firm has a market cap of $13.82 billion, a P/E ratio of -59.67, a PEG ratio of 2.83 and a beta of 1.40. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $303.30. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm’s 50 day moving average price is $256.31 and its two-hundred day moving average price is $202.66.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 11.33 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.